ABSTRACT
·AIM:To analyze the clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration ( ARMD) .·METHODS: Clinical data of patients with wet age-related macular degeneration received treatment of ranibizumab at our hospital from 2015 to 2017 were analyzed. At 1mo after treatment, the clinical efficacy, ocular hemodynamics and ocular inflammation were evaluated.·RESULTS: A total of 41 patients were analyzed. After treatment, patients got significantly increased in LogMAR (0. 651 ± 0. 067 vs 0. 321 ± 0. 049; t= 25. 460, P<0. 01 ) and decreased in central foveal thickness ( 239. 1 ± 51. 9μm vs 452. 9±69. 8μm;t=15. 740, P<0. 01). There was no serious complication during treatment period. After treatment, the levels of TNF-α (13. 1±4. 1ng/L vs 16. 1±3. 5ng/L; t=3. 563, P<0. 01) and IL-6 (12. 1±1. 9ng/L vs 13. 8±2. 5ng/L;t = 3. 467, P < 0. 01 ) in aqueous fluid decreased significantly. There was no significantly changes of blood flow volume of central retinal artery and ophthalmic artery at peak systolic velocity and end diastolic velocity before and after treatment (P>0. 05).·CONCLUSION: In the treatment of wet age- related macular degeneration, the ranibizumab shows a good therapeutic effect without serious adverse drug reactions.
ABSTRACT
·AIM:To analyze the effect of Conbercept for exudative age-related macular degeneration ( ARMD) .·METHODS: There were 21 eye of 21 patients with exudative ARMD from January 2016 to January 2017 included. All the patients were treated with intravitreal injection of conbercept 0. 5mL (0. 5mg) and followed up for 3mo. The best corrected visual acuity ( BCVA) and central macular thickness (CMT) before and 1wk, 1 and 3mo after treatment were observed.·RESULTS:The BCVA and CMT before and 1wk, 1 and 3mo after treatment were 0. 9±1. 4, 0. 7±1. 2, 0. 5±1. 1 and 0. 4±0. 9. BCVA after treatment were different at different time (F=49. 12, P<0. 001); BCVA at 1wk and 1mo after treatment were not different compared with before treatment ( P> 0. 05 ); that at 3mo were significantly different compared with before (P<0. 05). There were 19 eyes with improved BCVA at 3mo after treatment, unchanged in 2 eyes. CMT before and at 1wk, 1 and 3mo were 404. 25±68. 76, 354. 25±43. 12, 271. 75±32. 30, 218. 30± 24. 70μm. CMT at different time were significantly different (F=2487. 45, P<0. 001);CMT at 1wk, 1 and 3mo were different compared with before treatment ( P <0. 001). There were no severe complications found.·CONCLUSION: Intravitreal injection of conbercept for exudative ARMD is remarkable.
ABSTRACT
AIM: To observe clinical efficacy of the intravitreal injection of conbercept treatment for exudative age -related macular degeneration. METHODS:Prospective study. Totally 112 senile patients (112 eyes) with exudative macular degeneration were randomly divided into study group and the control group, 56 cases in each group. The study group were treated with intravitreal injection of conbercept. The control group received conservative treatment. Uncorrected visual acuity and foveal retinal thickness were observed before and after treatment in the two groups. RESULTS: Visual acuity of study group improved significantly, and the most obvious improvement was observed at 6mo after treatment. Foveal retinal thickness of study group was reduced after treatment, and the most obvious decrease was observed at 6mo after treatment.CONCLUSION: Intravitreal injection of conbercept can improve visual acuity reduced foveal thickness in senile patients with exudative age - related macular degeneration.
ABSTRACT
Age-related macular degeneration ( AMD ) is a kind of age-related blinding degenerative fundus lesions, totally about 30 million patients suffering from AMD all over the world, with about 500 000 people blind for it yearly. As the development of economy and the aging of the population intensified, incidence of AMD indicates a trend of rising year by year, being the third major cause of blindness in our country. At present, the pathogenesis of AMD is not fully clear, as reported it may be related to oxidative stress, inflammatory immune response, VEGF and genetic manipulation. Clinical treatments mainly include photodynamic therapy, drug therapy, radiation therapy, laser photocoagulaory operation, the pupil warm treatments, Chinese medicine and intravitreous injection VEGF antagonists such as Ranibizumab, Conbercept and so on. ln this issue, we mainly expound on the progress in the epidemiological studies of AMD, especially elaborate the progress made on genetic manipulation in recent years.
ABSTRACT
Photodynamic therapy ( PDT ) is a new technique to diagnose and treat diseases with photodynamic effect produced by photosensitizer and light, and is now a main method of treating exudative age - related macular degeneration ( AMD ) . ln recent years, with the development of science and technology, combinations of PDT have become a research hot spot. ln this paper, we reviewed the research status of treatments on exudative AMD with PDT combined anti-VEGF drugs.
ABSTRACT
?A great number of miRNAs have been shown to play critical roles in pathological angiogenesis, the oxidative stress response, immune response and inflammation, all of which have been shown to have important roles in the pathogenesis and progression of age- related macular degeneration ( AMD) . Here we reviewed the pathological processes involved in AMD and the roles of miRNAs in these processes, and discussed potential miRNAs-based therapeutics for AMD.
ABSTRACT
?Age-related macular degeneration ( AMD) is one of the main leading causes of irreversible damage eyesight over the 50 years old people. Genetic factors play an important role in the occurrence and development of AMD. ln recent years, the studies found that complement factor H ( CFH) gene has obvious correlation with the incidence of AMD. ln this article, we reviewed the researches on the CFH in AMD.
ABSTRACT
To compare subfoveal choroidal thickness (SFCT) between cases with non-neovascular age-related macular degeneration ( AMD) and neovascular AMD by optical coherence tomography ( OCT ) and to evaluate the contribution of choroidal thickness (CT) measurements to the understanding of pathogenesis of neovascularization in AMD. ●METHODS: Fourty - eigth eyes of 24 patients who had neovascular AMD in one eye and non- neovascular AMD in the other eye were included in this retrospective, cross-sectional study as study group. Forty eyes of healthy,age and axial length matched individuals were selected as the control group. Eyes with drusen and/ or pigmentary changes were included in the non - neovascular AMD subgroup. Eyes with subretinal or intraretinal fluid and/orlipid exudation due to the choroidal neovascularization were included in the neovascular AMD subgroup. OCT measurements were performed with RTVue 100-2 (V 5. 1, Optovue, Fremont, CA, USA) perpendicularly from the outer part of the hyperreflective line ( retinal pigment epithelial layer) to the line corresponding to the choroido-scleral junction. Choroidal thickness was measured at 7 different points, 500μ m intervals up to 1500μ m temporal and nasal to the fovea in the study group and compared statistically between subgroups. ●RESULTS: The mean age of patients was 72. 4±8. 97 (60-82)y. The mean age of healthy individuals was 71. 2±8. 8 (58- 81) y. Mean SFCT of neovascular AMD group were significantly thicker than non- neovascular AMD group (P0. 05). ln neovascular AMD group, there was a statistically significant difference between the mean SFCT and the mean temporal-nasal choroid thickness (P ●CONCLUSlON: Choroidal thickness measurements with OCT device can make a contribution to the understanding the phatophysiology of AMD and large prospective studies should be conducted to understand why SFCT was thicker in neovascular AMD.
ABSTRACT
Age - related macular degeneration ( AMD ) is the leading cause of irreversible visual loss in elderly people among white - dominated population. At percent, treatment for AMD includes anti - vascular endothelial growth factor antibody ( Anti- VEGF ) drug treatment, photodynamic therapy ( PDT ) , topical application of triamcinolone acetonide ( TA ) and laser therapy ( nanosecond laser) etc. Through comparative analysis of different treatment methods of AMD, we review the mechanism, clinical efficacy, adverse events and cost effectiveness to provide the basis for clinical treatment.
ABSTRACT
AIM: To evaluate the safety and efficacy of intravitreal bevacizumab ( avastin ) injection in patients with exudative age related macular degeneration ( AMD) . METHODS: The records of patients treated with intravitreal injection of 1. 75mg bevacizumab for AMD were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fundus fluorescein and/or indocyanine green angiography. Observation was made on the best corrected visual acuity ( BCVA) , intraocular pressure, and the changes of lens, vitreous, central retinal thickness (CFT) and total macular volume (TMV), at 1d, 3d, 7d, 1mo and 6mo after the treatment and then compared with those of pre - operation. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. And all cases were followed up at least 6mo. An intravitreal injection of bevacizumab (1. 75mg) was given once every 6wk. RESULTS:All 50 eyes of 48 patients with the average of 58±20. 46 years old were included. The mean baseline of BCVA and CFT were 0. 82±0. 53, and 364. 97±151. 83μm respectively. Although there was no significant decrease in mean CFT and TMV one week after the injection, the mean BCVA had significant improvement. At the last visit of 9. 7mo follow - up, BCVA, CRT and TMV showed significant improvements over baseline values. BCVA was improved by at least two lines in 32 eyes (64%),remained stabilization in 18 eyes (36%) at the last visit. A total of 98 injections were performed and the average number of injections was 1. 98 for each eye in the group. About 50%of re - injections gained at least two lines of vision improvement one week postoperatively. There were no serious adverse events during the treatment. CONCLUSION: Intravitreal bevacizumab ( avastin ) injection for managing CNV due to age-related macular degeneration is safe and few side effects. Intravitreal avastin associated with improvement in visual acuity ( VA ) , which can reduce macular edema and choroidal neovascularization leakage. But a prolonged treatment effect needs further observation.
ABSTRACT
AIM: To better reveal the changing process of macula area after photodynamic therapy (PDT), the changes of tomographic imaging on macular fovea optical coherence tomography ( OCT ) scan at different follow- up time points after treating age-related macular degeneration ( AMD) by PDT were investigated. METHODS: This cohort study included 30 eyes of 26 patients diagnosed as AMD. The dosage of verteporfin was calculated according to manufacturer's instruction. All participants got FFA, ICG, OCT scan and best corrected visual acuity before and followed up for 2wk, 1, 2, 3mo after PDT. The standard five lines combined with 6 lines OCT scan covered key parts of lesion and the scan locations before and after were kept the same. The bilaminar foveal thickness (BFT), outer high reflectivity band thickness ( OHRBT ) , and the total area of intraretinal fluid ( IRF ) and subretinal fluid ( SRF ) were measured at different time points. The relationship between the changes and follow up time was analyzed. Statistical analysis of the data was performed using SPSS for windows version 13. 0. RESULTS: There months after treatment, an improvement of 2 lines or better on the Snellen chart was achieved on 22 eyes, visual acuity of 3 eyes without significant change, 3 eyes got decreased, 2 cases lost follow up. The average macular thickness of improved 22 eyes before treatment was 722. 5±55. 6μm, 2wk after treatment, 708. 3±45. 3μm, 1mo, 584. 4±49. 3μm, 2mo, 430. 7±50. 2μm and 180. 6 ±36. 3μm at 3mo. The OHRBT before and after treatment respectively were 302. 3 ±50-2μm, 277. 5±42. 3μm, 202. 7±40. 1μm, 180. 6±35. 7μm, 100. 8±22. 9μm. The total area of both IRF and SRF was estimated as 0. 34±0. 12mm2 , 0. 25±0. 07mm2 , 0. 10±0-05mm2 , 0. 08±0. 04mm2 , 0. 05±0. 01mm2 . CONCLUSION:SRF and retinal edema of patients with AMD were absorbed 1mo after PDT, and the BFT, OHRBT were significantly tend to be thin.
ABSTRACT
Age-related macular degeneration(AMD), the most common cause of irreversible blindness over 50 years in developed countries, is a degenerative disease occurs with age. The prevalence rate in our country is also increasing by year and the pathogenesis is still undiscovered. In this review, we focus on the associated risk factors reported in recent years, aim to further understand the pathogenesis of AMD.
ABSTRACT
AlM: To establish the frequency, associations and risk factors for age-related macular degeneration ( AMD ) in hospital population. METHODS: ln this hospital based study, 589 subjects above 60 years of age were screened randomly for AMD. Participants underwent ocular evaluation and were interviewed for lifestyle variables and dietary intake of carotenoids by structured food frequency questionnaire. AMD was defined according to the international classifications and grading system. RESULTS: Either form of AMD was detected in 48 participants. AMD was significant among diabetes, diabetic retinopathy, body mass index, heavy cigarette smokers and alcoholics ( P CONCLUSlON: Higher dietary intake of carotenoids, especially L/Z, is associated with lower risk for AMD. Risk of AMD is prevalent among subjects with diabetes. Cessation of smoking and alcohol may reduce the risk of AMD in this population.